Laboratory Corp of America Holdings Stock News

BURLINGTON, N.C. , Sept. 29, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the third quarter of

Investors are increasingly optimistic about Labcorp (LH) due to its progress in hospital partnerships.

Labcorp's (LH) Early Development Research Laboratories business continues to be constrained by NHP-related supply-chain issues.

While the glitz and glamour of the hottest technology firms organically command our attention, investors should earmark some time for researching value stocks to buy. Fundamentally, these under-the-ra

MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how EYE, CAH and HSIC are poised ahead of their earnings releases.

A rise in organic revenues, acquisitions, net of divestitures and foreign currency translation drive LabCorp's (LH) Q2 revenues.

Laboratory Corporation of America Holdings (NYSE:LH ) Q2 2023 Earnings Conference Call July 27, 2023 9:00 AM ET Company Participants Chas Cook – Vice President-Investor Relations Adam Schechter –

Carter Worth, Worth Charting CEO, joins 'Power Lunch' to give his read on the technicals, looking at stocks on the verge of a breakout.

Laboratory Corporation of America Holdings shares have been hurt by the boom-bust cycle induced by the pandemic. Tough comparables should run off in the coming quarters, as the company is simplifying

LabCorp's (LH) latest partnership will significantly assist patients gain access to cutting-edge, potentially life-saving medication.

Labcorp (LH) completes the planned spin-off of Fortrea to operate as an independent clinical development business.

While the spinoff deal is positive for Labcorp, investors used the opportunity to sell on the news. Labcorp will do a $1 billion stock repurchase program and pay down debt.

Labcorp LH, +0.35% said Monday it completed the spin-off of Fortrea FTREV, -3.98% as an independent contract research organization (CRO) that specializes in Phase I-IV clinical trial management, patie

BURLINGTON, N.C. , June 29, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, will release its financial results for the second quarter of 2023 before the market opens

Laboratory Corporation has visible headwinds to growth ahead. The company's return on capital employed has lagged behind the required rate of return in the last two periods. Net-net, reiterate that LH